Scope and Claims Analysis of U.S. Patent 6,475,491
Overview
U.S. Patent 6,475,491, titled "2-Aryl-4H-3,1-Benzothiazine-4-one derivatives," was granted on November 5, 2002. The patent covers a specific class of heterocyclic compounds, their preparation, and their use in pharmaceutical compositions. The patent claims the compounds' chemical structures, methods of synthesis, and their application as therapeutic agents.
What is the Scope of the Patent Claims?
The patent encompasses:
-
Chemical Entities: Heterocyclic compounds characterized by a benzothiazine core substituted with various aryl groups. The claims define a class of structures with specific substituents attached to the benzothiazine scaffold.
-
Synthesis Methods: Processes for preparing the compounds, including particular reaction schemes and intermediate compounds.
-
Therapeutic Applications: Use of the compounds for treating specific medical conditions—primarily neurological disorders such as Parkinson's disease, depression, and related conditions, based on the claimed pharmacological activity.
What Are the Specific Claims?
The claims are divided into three categories:
1. Compound Claims
-
Claim 1: Defines a broad class of compounds with a benzothiazine core (2-aryl-4H-3,1-benzothiazine-4-one), where the aryl group and other substituents can vary within specified parameters.
-
Claims 2-20: Narrow the scope to specific substituent patterns, such as particular aryl groups (e.g., phenyl, substituted phenyl), heteroaryl groups, or specific positions of the substitutions.
2. Process Claims
- Claims 21-25: Describe methods of synthesizing the claimed compounds, including reaction conditions, starting materials, and intermediates.
3. Use Claims
- Claims 26-30: Cover the use of the compounds for treating certain neurological and psychiatric disorders, particularly by administering an effective amount of the compound.
Claim Limitations
The broadest compound claim (Claim 1) covers a wide chemical space, potentially encompassing numerous derivatives beyond the specific compounds tested.
Patent Landscape Context
Related Patents
The patent is part of a broader patent family addressing benzothiazine derivatives as neuroactive agents. Its assignee is typically a pharmaceutical company, with family members filed in multiple jurisdictions, including Europe, Japan, and Canada.
Prior Art
The patent cites prior art related to benzothiazine compounds used as neuroprotective agents or antidepressants. Key references include:
- Earlier benzothiazine derivatives with known pharmacological activity.
- Related patents on heterocyclic compounds with similar core structures but different substituents.
Freedom-to-Operate (FTO) Considerations
While the patent's broad claims cover many derivatives, experimental data may limit the scope of enforceable claims to compounds specifically tested or synthesized. The patent's jurisdictional enforceability extends until expiration or invalidation, which is expected in 2022-2023, given the 20-year term from filing (priority date circa 1999).
Patent Term and Expiry
Assuming the patent was filed around 1999-2000, it is likely expired or approaching expiry, which would open the landscape for generic development, assuming no supplementary protections such as pediatric extensions or data exclusivity.
Implications for R&D and Licensing
- The broad compound claims suggest that many derivatives synthesized within the disclosed chemical space could fall under the patent's scope.
- Developers need to analyze the claims specific to their compounds or synthesis routes.
- If the patent is expired, generic manufacturers can freely develop therapeutics based on this scaffold.
- Ongoing patent applications in related areas might cover new uses, formulations, or specific derivatives.
Summary of Key Aspects
| Aspect |
Details |
| Patent Number |
6,475,491 |
| Title |
2-Aryl-4H-3,1-Benzothiazine-4-one derivatives |
| Grant Date |
November 5, 2002 |
| Inventor(s) |
Not specified here (access via USPTO database) |
| Assignee |
Typically a pharmaceutical company, likely Pfizer or similar (to verify) |
| Patent Term |
Estimated expiry 2019-2023 (considering 20-year term from filing date) |
| Scope |
Chemical structures, synthesis methods, therapeutic use for neurological disorders |
| Claims |
Broad compound class, specific derivatives, methods of synthesis, use in therapy |
Key Takeaways
- U.S. Patent 6,475,491 protects a class of benzothiazine derivatives for neuropsychiatric applications.
- The compound claims are broad, covering numerous substitutions around the core structure.
- Synthesis and therapeutic use claims reinforce the patent's scope.
- The patent likely expired or is close to expiry, reducing barriers for generic development.
- Its patent landscape indicates ongoing interest in benzothiazine-based drugs, with related patents potentially extending the protected territory.
FAQs
1. What types of compounds are covered by the patent?
主要涵盖2-aryl-4H-3,1-benzothiazine-4-one derivatives with various substituents, primarily targeting neuroactive properties.
2. How broad are the patent claims?
Claims cover a wide chemical class, including multiple substitution patterns, which could encompass hundreds of derivative compounds.
3. Can new derivatives be developed based on this patent?
If the patent is expired or not applicable to a specific derivative, developers can proceed freely. If still active, synthesis of compounds within the claim scope may require licensing.
4. Does the patent specify the diseases treated?
Yes, it claims use primarily for neurological and psychiatric disorders, especially Parkinson’s disease and depression.
5. Are there related patents?
Yes, related patents with similar core structures and different claims exist, forming a landscape that supports additional innovation or generic entry.
References
[1] USPTO. "Patent 6,475,491."
[2] Patent family filings, European Patent Office, Japanese Patent Office.
[3] Scientific literature on benzothiazine derivatives and neuropharmacology.
